Related Experiment Videos
Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy
Journal of Clinical Pharmacology
|August 1, 1991
Summary
Long-term use of antiparkinson drugs alongside neuroleptics for schizophrenia is debated. Evidence supports their use in preventing extrapyramidal side effects, benefiting most patients.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- The efficacy of long-term neuroleptic treatment for schizophrenia is established.
- The role of concurrent antiparkinson drugs in managing side effects remains controversial.
Purpose of the Study:
- To evaluate the necessity and efficacy of prolonged antiparkinson drug use in schizophrenic patients.
- To analyze the benefits and risks of prophylactic antiparkinson drug administration.
Main Methods:
- Systematic review of double-blind, placebo-controlled studies on antiparkinson drug withdrawal.
- Critical assessment of methodological and statistical quality of included studies.
Main Results:
- Most existing studies on antiparkinson drug withdrawal exhibit significant flaws.
- Evidence suggests that long-term antiparkinson drug use is beneficial for preventing extrapyramidal side effects.
Conclusions:
- Prophylactic antiparkinson drug use in schizophrenic patients warrants careful consideration of benefits versus risks.
- The majority of patients may experience advantages from maintenance antiparkinson therapy.